Showing results (121-130 of 307) with videos related to

Sort By:
Pageof 31
Journal of the Neurological Sciences|February 14, 2018
The nosology of tardive syndromesKaren Frei, Daniel D Truong, Stanley Fahn, et al.
Neuropsychiatric Disease and Treatment|April 3, 2018
Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's diseaseRobert A Hauser, Aaron Ellenbogen, Sarita Khanna, et al.
Neurology. Clinical Practice|June 5, 2023
Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HTStuart H Isaacson, Mark Goldstein, Rajesh Pahwa, et al.
Movement Disorders Clinical Practice|May 22, 2018
Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102Stuart H Isaacson, Stanley Fahn, Rajesh Pahwa, et al.
Journal of Neurology|March 28, 2024
Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label studyJan Kassubek, Stewart A Factor, Ernest Balaguer, et al.
Frontiers in Neurology|April 12, 2021
Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's DiseaseRobert A Hauser, Ryan R Walsh, Rajesh Pahwa, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 10, 2014
Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B)Robert A Hauser, Stuart Isaacson, Jerome P Lisk, et al.
Parkinson'S Disease|January 25, 2021
Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical PracticeKhashayar Dashtipour, Fiona Gupta, Robert A Hauser, et al.
Parkinson'S Disease|March 10, 2021
Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion SurveyRobert A Hauser, Ghazal Banisadr, Kara Vuong, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 6, 2008
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's diseaseRobert A Hauser, Michel Panisset, Giovanni Abbruzzese, et al.
Pageof 31